MTCR News and Press, Metacrine Inc. From 08/09/22

Metacrine press release ( NASDAQ: MTCR ): Q2 Net loss was $6.3 million for the three months ended June 30, 2022, as compared to $15.6 million for prior-year period. Cash, cash equivalents and short-term investments were $55.5 million as of June 30, 2022. Fo...

SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its second-quarter 2022 financial results. “We have made meanin...

Arrowhead Pharmaceuticals ( ARWR ), a clinical-stage biotech focused on RNA interference (RNAi) therapeutics surged on above average volume on Wednesday in solidarity with several other drug developers targeting the liver disease, non-alcoholic steatohepatitis (NASH). Despite ...

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its first-quarter 2022 financial results and provided a business update. ...

SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today reported its fourth-quarter 2021 financial results. “We continue to dev...

Metacrine (NASDAQ:MTCR) announced that Ms.Trisha Millican has resigned from her CFO position; she will remain with the company until Mar.31 foe ensuring a smooth transition. Mr. Michael York, currently SVP, business development and commercial strategy, has been promot...

SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, today announced that Ms. Trisha Millican has resigned her position as chief financial offic...

Metacrine (NASDAQ:MTCR) is undertaking restructuring, which includes a staff reduction of ~50% primarily consisting of its research organization. Asa results, the company has also discontinued preclinical development of its hydroxysteroid dehydrogenase (HSD) program. The company said the rest...

U.S. FDA clears IND to evaluate MET642 for the treatment of ulcerative colitis Sufficient capital to complete Phase 2 IBD trial SAN DIEGO, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiate...

Metacrine (NASDAQ:MTCR) has announced the resignation of Chief Medical Officer (CMO) Hubert Chen. Chen will step down effective December 31, 2021. Metacrine CEO Preston Klassen is likely to assume responsibility for the company's ongoing clinical trials and future clinical operations. MTCR&#x...